The Bacteriophage Therapy Market was valued at $220.00 Million in 2025 and is projected to reach $890.02 Million by 2035, growing at a CAGR of 15.0 percent over 2026 to 2035, according to Strategic Revenue Insights. Antimicrobial resistance is the largest driver, adding 5.5 percentage points to annual growth, because phage attack bacteria by a different mechanism and can work on strains that no longer respond to antibiotics.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/bacteriophage-therapy-market
Bacteriophage Therapy Market Key Takeaways
- Market value grows 4.0x, from $220.00 Million in 2025 to $890.02 Million in 2035, with a downside case of $560.00 Million and an upside of $1.30 Billion.
- Lytic phage is the largest type at 62 percent of 2025 value; engineered phage cocktails grow fastest at 18.3 percent a year.
- Respiratory infections are the largest and fastest growing application at 29 percent share and 16.7 percent CAGR, reaching $299.62 Million by 2035.
- Hospitals are the main buyers at 57 percent, followed by research institutes at 24 percent; specialty clinics grow fastest at 16.4 percent.
- North America leads with 36 percent share; Asia Pacific grows fastest at 16.4 percent and reaches $241.60 Million by 2035.
What Is Driving Growth
Antimicrobial resistance adds 5.5 percentage points, as hospitals face longer stays, repeat surgery and higher death rates when bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus resist standard antibiotics. Clinical trial progress adds 4.5 points, because controlled studies build the evidence on safety, dose and effect that regulators, hospital committees and payers need. Engineered phage platforms add 3.5 points by widening the range of bacteria a product can treat, and public funding and compassionate use add 2.5 points. Regulatory uncertainty removes 2.0 points and manufacturing standardization removes 1.5 points.
Segments, Regions and Key Players
By type, lytic phage holds 62 percent of 2025 value because it is already in use, while engineered phage cocktails grow fastest at 18.3 percent. By application, respiratory infections lead at 29 percent, and wound and skin infections reach $215.14 Million by 2035. Hospitals hold 57 percent of value, research institutes 24 percent and specialty clinics 19 percent. North America holds 36 percent of 2025 value at $79.20 Million and grows at 14.2 percent, Europe holds 30 percent and grows at 14.4 percent, and Asia Pacific holds 24 percent and grows fastest at 16.4 percent.
Armata Pharmaceuticals leads with 10.5 percent share, followed by Adaptive Phage Therapeutics at 8.5 percent, BiomX at 7.5 percent, Locus Biosciences at 7.0 percent, Intralytix at 6.0 percent, Phaxiam Therapeutics at 5.0 percent and Eligo Bioscience at 4.0 percent. The five largest companies hold about 40 percent of revenue, and a single clear regulatory result could reshape the table.
Frequently Asked Questions
How big is the Bacteriophage Therapy Market?
The market was worth $220.00 Million in 2025 and is projected to reach $890.02 Million by 2035, a 15.0 percent CAGR from 2026 to 2035.
What is bacteriophage therapy?
It is the therapeutic use of bacteriophages, viruses that infect and kill specific bacteria, including lytic phage, lysogenic phage and engineered phage cocktails designed to reach more strains.
Which region grows fastest?
Asia Pacific grows fastest at 16.4 percent a year and reaches $241.60 Million by 2035, while North America remains the largest region at 36 percent of 2025 value.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com